Check-Cap (NASDAQ:CHEK) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Check-Cap (NASDAQ:CHEK) in a research note released on Friday morning. The brokerage issued a sell rating on the medical research company’s stock.

Check-Cap Price Performance

NASDAQ CHEK opened at $0.76 on Friday. Check-Cap has a 1-year low of $0.56 and a 1-year high of $3.45. The company has a market capitalization of $4.46 million, a P/E ratio of -0.25 and a beta of 0.16. The business has a 50 day moving average price of $1.11 and a 200 day moving average price of $1.27.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.